α1-blockers in hypertension

Current Medical Research and Opinion

Volumn 15, Issue 2, 1999, Pages 95-103

  Sever, Peter S ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Antihypertensive therapy; Hypertension; 1 blockers

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; GLUCOSE HOMEOSTASIS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; SIDE EFFECT; SINGLE BLIND PROCEDURE;

EID: 0033057420     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999909113369     Document Type: Article

References (50)

1. Castelli, W. P. (1984). The epidemiology of coronary heart disease: the Framingham Study. Am. Heart J., 27, 4-12.
2. Sever, P. (1995). The heterogeneity of hypertension: why doesn't every patient respond to every hypertensive drug? J. Hum. Hyperten., 9, S33-36.
3. Dahlöf, B., Lindholm, L. H., Hansson, L., et al. (1991). Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet, 338, 1281-1285.
4. Lever, A. F. and Ramsay, L. E. (1995). Treatment of hypertension in the elderly. J. Hyperten., 13, 571-579.
5. Roberts, W. C. (1988). Blood lipid levels and antihypertensive therapy. Drugs, 36 (Suppl 2), 6-10.
6. Houston, M. C. (1989). New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertension. Am. Heart J., 117, 911-951.
7. Flack, J. M. (1991). Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am. J. Med., 91 (Suppl 1A), 11S-21S.
8. Poulter, N. (1991). Management of multiple risk factors for coronary heart disease in patients with hypertension. Am. Heart J., 121, 246-250.
9. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. (1997). Arch. Intern. Med., 157, 2413-2446.
10. Sever, P., Beevers, G., Bulpitt, C., et al. (1993). Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ, 306, 983-987.
11. World Health Organization/International Society of Hypertension Guidelines Subcommittee (1993). 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J. Hyperten., 11, 905-918.
12. Materson, B. J., Reda, D. J., Cushman, W. C., et al. (1993). Single-drug therapy for hypertension in men. N. Engl. J. Med., 328, 914-921.
13. Attwood, S., Bird, R., Burch, K., et al. (1994). Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J. Hyperten., 12, 1053-1060.
14. Messerli, F. H. (1992). Combination therapy in hypertension. J. Hum. Hypertens., 6 (Suppl 2), S19-S21.
15. MacConnachie, A. M. and McLean, D. (1995). Low dose combination antihypertensive therapy. Additional efficacy without additional adverse effects? Drug Safety, 12, 85-90.
16. 1-inhibitors: first- or second-line antihypertensive agents? Cardiology, 83, 150-159.
17. Fulton, B., Wagstaff, A. J. and Sorkin, E. M. (1995). Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs, 49, 295-320.
18. Neaton, J. D., Grimm, Jr R. H., Princeas, R. J., et al. (1993). Treatment of mild hypertension study (TOMHS): final results. JAMA, 270, 713-724.
19. Johnson, B. F. and Danylchuk, M. A. (1989). The relevance of plasma lipid changes with cardiovascular drug therapy. Med. Clin. North Am., 73, 449-473.
20. Feher, M. D., Henderson, A. D., Wadsworth, J., et al. (1990). α-blocker therapy: a possible advance in the treatment of diabetic hypertension - results of a crossover study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. J. Hum. Hyperten., 4, 571-577.
21. Huupponen, R., Lehtonen, A. and Vähätalo, M. (1992). Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur. J. Clin. Pharmacol., 43, 365-368.
22. 2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes, 44, 665-671.
23. Maheux, P., Facchini, F., Jeppesen, J., et al. (1994). Changes in glucose, insulin, lipid, lipoprotein and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Am. J. Hyperten., 7, 416-424.
24. Agabiti-Rosei, E., Muiesan, M. L., Rizzoni, D., et al. (1992). Reduction of left ventricular hypertrophy after long-term antihypertensive treatment with doxazosin. J. Hum. Hyperten., 6, 9-15.
25. Liebson, P. R., Grandits, G. A., Dianzumba, S., et al. (1995). Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation, 91, 698-706.
26. Rosenthal, J. (1988). Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. Am. Heart J., 116, 1763-1766.
27. Manos, J. (1991). A long-term study of doxazosin in the treatment of mild or moderate essential hypertension in general medical practice. Am. Heart J., 121, 346-351.
28. Langdon, C. G. and Packard, R. S. (1994). Doxazosin in hypertension: results of a general practice study in 4809 patients. Br. J. Clin. Pract., 48, 293-298.
29. Lund-Johansen, P. (1979). Hemodynamic consequences of long-term β-blockade: a five-year follow-up study of atenolol. J. Cardiovasc. Pharmacol., 1, 487-495.
30. Searle, M., Dathan, R., Dean, S., et al. (1990). Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur. J. Clin. Pharmacol., 39, 299-300.
31. Wing, L. M. H., Russell, A. E., Tonkin, A. L., et al. (1991). Doxazosin and atenolol in essential hypertension: a placebo-controlled factorial study evaluating comparative and combined safety and efficacy. J. Hyperten., 9 (Suppl 6), S495-S496.
32. 1-blockade and angiotensin converting enzyme inhibition in essential hypertension. J. Hyperten., 9 (Suppl), S362-S363.
33. Englert, R. G. and Mauersberger, H. (1988). A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am. Heart J., 116, 1826-1832.
34. Brown, M. J. and Dickerson, J. E. (1995). α-Blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. J. Hyperten., 13, 701-707.
35. Hansson, L. and Himmelmann, A. (1991). Calcium antagonists in antihypertensive combination therapy. J. Cardiovasc. Pharmacol., 18 (Suppl 10), S76-S80.
36. Troffa, C., Manunta, P., Dessi-Fulgheri, P., et al. (1994). Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr. Ther. Res., 55, 22-31.
37. Englert, R. G. and Barlage, U. (1991). The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by β-blockers. Am. Heart J., 121, 311-316.
38. Black, H. R., Chrysant, S. G., Curry, C. L., et al. (1992). Antihypertensive and metabolic effects of concomitant administration of terazosin and methylclothiazide for the treatment of essential hypertension. J. Clin. Pharmacol., 32, 351-359.
39. Donnelly, R., Elliott, H. L., Meredith, P. A., et al. (1992). Combination of nifedipine and doxazosin in essential hypertension. J. Cardiovasc. Pharmacol., 19, 479-486.
40. Lavie, C. J., Ventura, O. and Messerli, F. H. (1991). Regression of increased left ventricular mass by antihypertensives. Drugs, 42, 945-961.
41. Leenen, F. H. H., Smith, D. L., Farkas, R. M., et al. (1987). Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive humans. Am. J. Med., 82, 969-978.
42. Yasumoto, K., Takata, M., Yoshida, K., et al. (1990). Reversal of left ventricular hypertrophy by terazosin in hypertensive patients. J. Hum. Hyperten., 4, 13-18.
43. Dahlöf, B., Penners, K. and Hansson, L. (1992). Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am. J. Hyperten., 5, 95-110.
44. Medical Research Council Working Party. (1985). MRC trial of treatment of mild hypertension: principal results. BMJ, 291, 97-104.
45. Medical Research Council Working Party. (1992). Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ, 304, 405-411.
46. Eisen, S. A., Miller, D. K., Woodward, R. S., et al. (1990). The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med., 150, 881-884.
47. Bittar, N. (1995). Maintaining long-term control of blood pressure: the role of improved compliance. Clin. Cardiol., 18 (Suppl III), 12-16.
48. Davis, B. R., Cutler, J. A., Gordon, D. J., et al. (1996). Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Am. J. Hyperten., 9, 342-360.
49. Sever, P. and Mackay, J. A. (1996). The hypertension trials. J. Hyperten., 14 (Suppl), S29-S33.
50. World Health Organization/International Society of Hypertension Guidelines Subcommittee (1999). 1999 guidelines for the management of hypertension. J. Hyperten., 17, 151-183.